We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Requests Suspending Hundreds of Drugs Over Indian CRO Data Flaws
EMA Requests Suspending Hundreds of Drugs Over Indian CRO Data Flaws
The EMA is recommending the European Commission suspend sales of more than 300 generic drug formulations approved using flawed bioequivalence studies conducted at two Micro Therapeutic Research Labs’ facilities in India.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor